Raltegravir pharmacokinetics during pregnancy
| Autor: | Watts, D Heather, Stek, Alice, Best, Brookie M, Wang, Jiajia, Capparelli, Edmund V, Cressey, Tim R, Aweeka, Francesca, Lizak, Patty, Kreitchmann, Regis, Burchett, Sandra K, Shapiro, David E, Hawkins, Elizabeth, Smith, Elizabeth, Mirochnick, Mark, IMPAACT 1026s study team |
|---|---|
| Rok vydání: | 2014 |
| Předmět: |
Adult
Clinical Sciences Reproductive Health and Childbirth HIV Infections Young Adult Pregnancy Raltegravir Potassium Virology Humans HIV Integrase Inhibitors Pediatric Postpartum Period Infectious Evaluation of treatments and therapeutic interventions HIV IMPAACT 1026s study team Pyrrolidinones Pregnancy Complications Good Health and Well Being Infectious Diseases 6.1 Pharmaceuticals Public Health and Health Services HIV/AIDS Female Pregnancy Trimesters raltegravir Infection pharmacokinetics |
| Zdroj: | Journal of acquired immune deficiency syndromes (1999), vol 67, iss 4 |
| Popis: | ObjectiveWe evaluated the pharmacokinetics (PK) of raltegravir in HIV-infected women during pregnancy and postpartum.MethodsInternational Maternal Pediatric Adolescent AIDS Clinical Trials 1026s is an ongoing prospective study of antiretroviral PK during pregnancy (NCT00042289). Women receiving 400 mg raltegravir twice daily in combination antiretroviral therapy had intensive steady-state 12-hour PK profiles performed during pregnancy and at 6- to 12-week postpartum. Targets were trough concentration above 0.035 μg/mL, the estimated 10th percentile in nonpregnant historical controls.ResultsMedian raltegravir area under the curve was 6.6 μg·h/mL for second trimester (n = 16), 5.4 μg·h/mL for third trimester (n = 41), and 11.6 μg·h/mL postpartum (n = 38) (P = 0.03 postpartum vs second trimester, P = 0.001 pp vs third trimester). Trough concentrations were above the target in 69%, 80%, and 79% of second trimester, third trimester, and postpartum subjects, respectively, with wide variability ( |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|